99% USP 3-(2,2,2-triMethylhydraziniuM)propionate dihydrate THP MET-88
99% USP CAS 76144-81-5 Mildronate Powder
Mildronate
CAS: 76144-81-5
MF: C6H14N2O2
MW: 146.18756
Chemical Properties White Crystalline Powder
Usage A novel pharmaceutical composition based on a reverse transcriptase inhibitor.
mildronate (also known as THP, MET-88) is a new cardioprotective drug. It was developed by the Latvian Institute of Organic Synthesis, and was first marketed by Grindeks in the former Soviet Union in 1989. It is a structural analogue of carnitine and its chemical name is 3-(2,2,2-trimethylhydrazine). Propionate dihydrate. After that, it was registered and listed in more than 20 countries including Russia, Turkey, India, and Romania.
The site of action is mitochondria, which improves myocardial energy metabolism at the cellular level. In view of the obvious difference between these drugs and other anti-myocardial ischemic drugs, they are also called cellular anti-ischemic drugs.
It is a structural analogue of carnitine and can compete to inhibit betaine butyrate hydroxylase, thereby inhibiting the biosynthesis of carnitine, and directly inhibiting the transport of carnitine-dependent fatty acids in the mitochondria. Inhibiting the biosynthesis of carnitine can reduce the concentration of free carnitine in cells and prevent the accumulation of acylcarnitine induced by isoproterenol. Therefore, the drug has a significant protective effect on the myocardium. While producing this protective effect, it has no significant impact on hemodynamic parameters, and there is no significant change in cardiac blood supply and cardiac oxygen consumption.
| Package |
carton drum with two plastic bags inside |
| Net weight |
25KG/Drum |
| Storage |
Sealed in cool and dry place to avoid moisture and light |
| Shelf life |
2 years when properly stored |
| Lead time |
1~3 days after confirmation |
More reports, please contact us freely.
Audited Supplier 
){kind=link}